ARTICLE | Product Development
Ironwood's local notion
How tissue-targeting may add new indications for Ironwood compounds
July 27, 2015 7:00 AM UTC
Ironwood Pharmaceuticals Inc. is exploring how tissue-specific distribution can give its products additional activity or different clinical profiles suitable for new indications. The company reported Phase I data last week for IW-1973, a stimulator of soluble guanylate cyclase that was designed to leave the vasculature and enter tissues to treat cardiovascular diseases.
Ironwood also is altering biodistribution to make next-generation versions of constipation drug Linzess linaclotide that will have different clinical profiles depending on where they act within the GI tract...